119 results about "Immunoadsorption" patented technology

The invention belongs to the field of immunological detection, and provides a double-antibody sandwich ELISA kit for detecting the content of human beta-NGF. The enzyme-linked immunosorbent assay kit constructed by the invention is based on a double-antibody sandwich method, and is combined with a biotin-streptavidin signal amplification system and an enzyme developing amplification system, so that the detection sensitivity and specificity are greatly improved, and low-content samples can be accurately and quickly detected. The kit shows excellent stability and specificity and can be used for quantitatively detecting the content of beta-NGF in samples such as human serum, cell supernatant or tissue homogenate, so that an objective detection basis is provided for diagnosis, curative effect evaluation and pathogenesis research of related diseases.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The invention discloses a high-affinity monoclonal antibody for recognizing group B streptococcus SIP (Session Initiation Protocol) protein or an antigen binding fragment thereof. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The lowest detection limit of the group B streptococcus SIP protein double-antibody sandwich enzyme-linked immunosorbent assay established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on the SIP protein is 0.32 ng / mL. The lowest detection limit of a group B streptococcus SIP protein double-antibody sandwich fluorescence immunochromatography assay method established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on SIP protein is 0.08 ng / mL, and the lowest detection limit on GBS bacterial liquid reaches 1 * 10 < 3 > CFU / mL, which is obviously higher than the lowest detection limit of the existing detection reagent and literature report; the method can be used for qualitative and quantitative detection of the group B streptococcus SIP protein.

The invention discloses a paralichthys olivaceus rhabdovirus G protein tandem antigen epitope peptide and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO: 1. The preparation method comprises the following steps: (1) firstly, analyzing structural characteristics of HIRRV-G protein, predicting B cell antigen epitopes of the HIRRV-G protein, screening the antigen epitopes with advantages on the basis of a prediction result, and synthesizing the antigen epitopes; (2) screening a candidate peptide fragment with high affinity through an enzyme-linked immunosorbent assay; and (3) sequentially connecting the high-affinity peptide fragment sequences meeting the requirements by using a GPGPG connexon, cloning the connected sequences into a pET-28a prokaryotic expression vector, and performing induced expression to obtain the tandem antigen epitope peptide. Compared with a full-length G protein, the tandem antigen epitope peptide is smaller in molecular weight, higher in stability and higher in hydrophilicity; a large number of specific antibodies can be induced in fish bodies, and the death rate of the paralichthys olivaceus infected by viruses is remarkably reduced. The method can be used for HIRRV diagnosis detection reagent and subunit vaccine development.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

The application discloses nanobodies against E protein of chikungunya virus and application in virus detection, and the nanobodies against E protein of chikungunya virus include N055 and 10G4 antibodies, and both have high affinity and binding activity with antigens. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by the nanobodies of the N055 and 10G4 antibodies can efficiently detect E protein of chikungunya virus and virus-like particles, and the detection sensitivity can reach 49 pg / mL, and the antibody combination has wide application prospects in diagnosis and pathogen detection of chikungunya virus disease.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

In accordance with at least one aspect of this disclosure, a method for preparing a patient for a diagnostic procedure and / or for receiving a therapy using a disease targeted drug is provided. The method can include the steps of a) identifying one or more soluble targets detectable in plasma of the patient; and b) extracorporeally removing the soluble targets from the plasma of the patient. Extracorporeally removing the soluble targets from the plasma of the patient can include using plasmapheresis or immunoadsorption to prepare a patient for a procedure using disease targeted treatment or diagnostics. Additionally, or alternatively, dose modulation can be used to proportionally increase the concertation of the diagnostic / treatment agent relative to the concentration of the soluble target in the blood, improving the outcome treatment and diagnostic procedures over conventional methods.

The invention provides a method for detecting new antibiotic pollutants in a water body sample by combining solid-phase extraction and enzyme-linked immunosorbent assay, which comprises the following steps: (a) selecting an organic solvent, so that R2 of a standard curve obtained by enzyme-linked immunosorbent assay of a standard substance containing the new antibiotic pollutants and an aqueous solution of the organic solvent is greater than 0.98; (b) determining the optimal concentration of the organic solvent by taking the quantitative detection interval, the sensitivity, the detection limit and the precision of enzyme-linked immunosorbent assay as evaluation indexes and combining a CRITIC weight method; and (c) preparing the new antibiotic pollutants enriched by the organic solvent selected in the step (a) through solid-phase extraction of the water body sample and water into a redissolved aqueous solution, and detecting the redissolved aqueous solution through enzyme-linked immunosorbent assay to determine the concentration of the new antibiotic pollutants in the water body sample, wherein the concentration of the organic solvent in the redissolved aqueous solution is the optimal concentration. The invention also provides a method for optimizing enzyme-linked immunosorbent assay.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention relates to the field of biological medicines, and discloses application of serum EPSTI1 in preparation of a product for diagnosing liver cancer and evaluating whether a liver cancer patient is resistant to a revatinib or not. The invention provides a detection means which is convenient and rapid in sampling, small in risk and relatively low in cost, the content of EPSTI1 in serum is detected through an enzyme-linked immunosorbent assay, a liver cancer patient and a non-liver cancer patient can be effectively distinguished, and a lovatinib drug-resistant liver cancer patient and a non-drug-resistant liver cancer patient can be effectively distinguished. Prognosis analysis shows that the serum EPSTI1 can be used as a marker for evaluating the prognosis state of the liver cancer patient taking the lenvatinib, and has important significance in improving the survival rate of the liver cancer patient.

The invention belongs to the field of biology, and particularly relates to a chemiluminescence kit for detecting CEACAM1, a use method and application, the chemiluminescence kit comprises a streptavidin magnetic particle working solution, a biotinylated carcino-embryonic antigen related cell adhesion molecule 1 capture antibody solution and an acridinium ester labeled carcino-embryonic antigen related cell adhesion molecule 1 detection antibody solution. Coupling of acridinium ester and the antibody is efficient and simple, repeatability is good, large-scale production and application are easy, a biotin-avidin amplification system (BAS system) is used in a reaction system, quantitative detection of ultramicro markers is more sensitive and more efficient, and compared with a traditional enzyme-linked immunosorbent assay method, the method has the advantages that the detection sensitivity is high, and the sensitivity is high. The magnetic particle chemiluminescence reagent disclosed by the invention has the advantages of low cost, stable and reliable result, high test flux, convenience in production, small batch difference, easiness in large-scale application and the like.

The application discloses a nano antibody against Ebola virus VP40 protein and application thereof in Ebola virus detection, wherein the nano antibody against Ebola virus VP40 protein is a 3E07 antibody. The nano antibody against Ebola virus VP40 protein prepared by the application has the characteristics of high sensitivity and wide binding spectrum. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by 3E07 and 3F06 antibodies can efficiently detect VP40 proteins and virus-like particles of various Ebola virus subtypes such as Zaire, Sudan and Beni, wherein the detection sensitivity of the Ebola virus VP40 protein of Zaire type can reach 0.039 ng / mL, and the antibody combination has a wide application prospect in the diagnosis and pathogen detection of Ebola virus disease.

The invention relates to an anti-ovarian antibody chemiluminiscence kit and a preparation method thereof. The kit comprises amino magnetic beads coated with anti-ovarian antibody recombinant protein, anti-human immune globulin labeled by alkaline phosphatase, an anti-ovarian antibody calibrator and a chemiluminiscence substrate. The method has the beneficial effects that the 7-day acceleration stability of the AOAb coated amino magnetic bead is improved to 95% or above, the signal-to-noise ratio is high, the correlation coefficient is greater than 0.999, the test repeatability CV is less than 3.5%, the reagent correlation and the magnetic bead stability can be better improved, and the test result is ensured to be accurate. By optimizing the amino magnetic bead cross-linking agent, 60 clinical samples are tested and compared with the result of a comparison manufacturer, the total coincidence rate is as high as 98%, and false positive can be effectively reduced. Meanwhile, a detection system is formed by matching with a Guilin superior chemiluminescence immunoassay analyzer IA-260, the testing amount per hour reaches 130 tests, and compared with a traditional colloidal gold immunochromatography method and a traditional enzyme-linked immunosorbent assay method, the detection speed is greatly increased, and the result optimization accuracy is greatly improved.

The invention relates to a nano antibody for specifically recognizing a tacrolimus-antibody compound and application of the nano antibody, and belongs to the technical field of biological detection. A variable region of the nano antibody has three complementary determining regions CDR1, CDR2 and CDR3, can specifically recognize a tacrolimus-antibody compound, and can be used for detecting drugs by a double-antibody sandwich method; the kit is widely suitable for various immunodetection technologies such as an enzyme-linked immunosorbent assay (ELISA), a chemiluminescence immunoassay (CLIA), an electrochemical luminescence immunoassay (ECLIA), a fluorescence immunoassay (FIA), an immunochromatography test strip method and the like. According to the method, the limitation of a traditional competition method is overcome, high-sensitivity, high-specificity and high-stability detection is realized, the method can be adapted to various detection platforms, and a portable pretreatment process without centrifugation can also be realized.

The invention relates to a Brucella lipopolysaccharide monoclonal antibody and a cELISA detection kit and detection method based on the same, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and is characterized in that the amino acid sequence of the heavy chain variable region is SEQ ID No.1, and the corresponding nucleotide sequence is SEQ ID No.2; the amino acid sequence of the light chain variable region is SEQ ID No.3, and the corresponding nucleotide sequence is SEQ ID No.4. The monoclonal antibody is only specifically combined with smooth LPS of brucella, and has no cross reaction with 21 pathogens such as rough brucella, yersinia O: 9 and the like. The sensitivity of a competitive enzyme-linked immunosorbent assay (cELISA) kit developed on the basis of the antibody reaches 1: 25600 and is improved by 200 times compared with that of a traditional method, the detection time is shortened to 90 min, the in-plate / inter-plate variable coefficient is lower than 9.87%, and the antibody is suitable for high-throughput screening of multi-host serum.

The invention belongs to the technical field of biotechnology and protein determination, and particularly relates to confining liquid as well as a preparation method and application thereof. Modified bovine serum albumin and recombinant casein polypeptide are used as core components of the confining liquid, hydroxypropyl-beta-cyclodextrin, polyglycerol fatty acid ester and other auxiliary components are added, and the confining liquid is prepared through a specific technology. The modified bovine serum albumin and the recombinant casein polypeptide have a synergistic effect, so that active sites of the detection carrier can be efficiently sealed; the stabilizing agent and other components are supplemented, so that the stability and compatibility of the confining liquid are improved. The confining liquid is simple and convenient in preparation process, controllable in cost, suitable for various detection carriers such as elisa plates and nitrocellulose membranes, capable of reducing non-specific binding and improving detection sensitivity, and suitable for various biological detection scenes such as enzyme-linked immunosorbent assay.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

The application belongs to the field of biology and relates to a nanobody targeting calexcin and a preparation method and application thereof, the nanobody targeting calexcin is successfully screened and prepared, and the nanobody-HRP fusion protein used for affinity identification in an enzyme-linked immunosorbent assay is successfully expressed; in combination with a phage-assisted continuous and discontinuous directed evolution (PACE) system, the nanobody screened is subjected to directed evolution, and stable mutation sites are found through sequence alignment analysis; it is proved through an indirect enzyme-linked immunosorbent assay and a luciferase complementation assay that the affinity of the nanobody after evolution to calexcin is improved by about 2 times.

The invention discloses cyclodextrin-mediated water-soluble rare earth nanoparticles and a synthesis method and application thereof in antibody coupling, and the method comprises the following steps: preparing uniform rare earth nanoparticles with different particle sizes by using a high-temperature thermal decomposition method, and carrying out self-assembly modification by using polyethylene glycol (PEG) derivative modification and carboxylated cyclodextrin (CM-CD) to obtain the cyclodextrin-mediated water-soluble rare earth nanoparticles. And coating the surfaces of the rare earth nanoparticles with PEG chain molecules or PEG (at) CM-CD composite molecules to obtain the modified water-soluble rare earth nanoparticles. And then mixing the modified water-soluble rare earth nanoparticles with 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS), introducing NHS ester, and carrying out covalent coupling with an antibody to obtain the antibody-coupled rare earth nano probe. An electron microscope, a zeta potential test and an enzyme-linked immunosorbent assay detection kit test prove that the water solubility and the dispersity of the rare earth nanoparticles can be improved by carboxylated cyclodextrin modification, and meanwhile, the loading capacity and the affinity of a coupling antibody are improved.

The invention discloses a colon cancer screening method and kit based on the lactic acid level of a DNA polymerase gamma (Polg) K947 site, and relates to the technical field of biological medicines. Immunohistochemical and serological experiments prove that the lactylation level of the Polg K947 is remarkably reduced in colon cancer patients, and the application value of the Polg K947 in colon cancer diagnosis is disclosed. The application specifically comprises the following steps: detecting the modification level in serum by adopting a specific recognition Polg K947 lactylated antibody through an enzyme-linked immunosorbent assay, taking the modification level as a biomarker for early screening and risk assessment of colon cancer, and providing a corresponding detection kit. The Polg K947 lactylation marker has high sensitivity and specificity, provides a new technical path for non-invasive colon cancer screening, and has a good clinical transformation prospect.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

The invention discloses a monoclonal antibody capable of simultaneously identifying mycobacterium tuberculosis secretory protein 64 of a wild type (W-MPT64) and a 63bp deletion mutant type (D-MPT64). The amino acid sequences of variable regions of a heavy chain and a light chain of the antibody are shown as SEQ ID NO.1 and SEQ ID NO.5. The lowest detection limits of W-MPT64 and D-MPT64 by a mycobacterium tuberculosis MPT64 double-antibody sandwich enzyme-linked immunosorbent assay and a fluorescence immunochromatography assay established by using the monoclonal antibody both reach 1.5625 pg / mL, which are significantly higher than the lowest detection limit in the prior art, and the monoclonal antibody can be used for qualitative and quantitative detection of mycobacterium tuberculosis secretory protein 64.

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The invention relates to application of arachidonic acid (ARA) in preparation of a medicine for treating sleep disorder related spontaneous abortion. Peripheral blood lipid metabolism sequencing analysis finds that the ARA content in peripheral blood serum of a patient suffering from sleep disorder and repeated pregnancy loss is most obviously reduced compared with that of a patient suffering from normal sleep and normal pregnancy; an enzyme-linked immunosorbent assay test shows that the content of ARA in decidua stromal cells (DSCs) of a patient with sleep disorder and repeated pregnancy loss is remarkably reduced compared with that of a pregnant person with normal sleep; after the endometrial stromal cells (ESCs) are subjected to ARA treatment, the in-vitro decidualization level is increased; the ARA inhibitor can be used for inhibiting the in-vitro deciduation level of the ESCs; compared with a mouse with normal sleep, the content of ARA in peripheral blood and DSCs of a mouse with sleep disorder is remarkably reduced, decidua is poor, and the abortion rate is increased; supplementing ARA can improve decidua disorder and high abortion rate caused by sleep disorder. Therefore, a potential target and a new idea are provided for diagnosis and treatment of repeated pregnancy loss related to sleep disorder.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-Caspr1 antibodies and its preparation method. The invention constructs an expression plasmid capable of highly expressing the Caspr1 antigen, transfects it into HEK293T cells, and modifies the original antigen sequence during construction to achieve normal membrane expression. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-Caspr1 antibodies based on cellular immunofluorescence assay. This invention, based on cellular immunofluorescence, avoids the limitations of flow cytometry, which is complex and requires expensive equipment. By modifying the protein expression mode to normal membrane expression, it avoids cell permeabilization, avoids false negatives caused by antigen conformational changes in enzyme-linked immunosorbent assay (ELISA) and Western blotting, and avoids false negatives caused by transmembrane expression due to transfection with the original Caspr1 sequence.